Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

Weitere Versionen anzeigen (1)

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R
Format:	Journal article
Sprache:	English
Veröffentlicht:	Springer International Publishing 2014

Ähnliche Einträge

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
von: Latimer, N, et al.
Veröffentlicht: (2014)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
von: Guerry, M, et al.
Veröffentlicht: (2012)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
von: Flossmann, O, et al.
Veröffentlicht: (2006)

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
von: Michael A Paley, et al.
Veröffentlicht: (2019-01-01)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Robson, J, et al.
Veröffentlicht: (2017)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
von: Basu, N, et al.
Veröffentlicht: (2014)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
von: Pearce, F, et al.
Veröffentlicht: (2017)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
von: Thomas Hellmark, et al.
Veröffentlicht: (2019-03-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
von: Fahidah Alenzi, et al.
Veröffentlicht: (2023-09-01)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
von: Valentina Binda, et al.
Veröffentlicht: (2021-12-01)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
von: Alan D. Salama
Veröffentlicht: (2020-01-01)

Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Cheng-Hua Weng, et al.
Veröffentlicht: (2019-12-01)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
von: Robson, J, et al.
Veröffentlicht: (2017)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
von: Saket Jha, et al.
Veröffentlicht: (2019-01-01)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
von: Xinyu Weng, et al.
Veröffentlicht: (2022-03-01)

Cardiovascular and Cerebrovascular Outcomes in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis
von: Shiyu Xiao, et al.
Veröffentlicht: (2024-01-01)

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Christopher Maximilian Arends, et al.
Veröffentlicht: (2020-06-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
von: Haiting Wu, et al.
Veröffentlicht: (2022-04-01)

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Marta Casal Moura, et al.
Veröffentlicht: (2022-11-01)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
von: Daisuke Tsukui, et al.
Veröffentlicht: (2021-01-01)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
von: Hellmich, B, et al.
Veröffentlicht: (2007)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
von: Laura S. van Dam, et al.
Veröffentlicht: (2020-12-01)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
von: Luqmani, R, et al.
Veröffentlicht: (2017)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
von: E. N. Vorkel, et al.
Veröffentlicht: (2024-12-01)

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Weijun Liu, et al.
Veröffentlicht: (2024-05-01)

Recent advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
von: Si-wei Tang, et al.
Veröffentlicht: (2024-03-01)

Oral Microbiota Profile in Patients with Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
von: Anders Esberg, et al.
Veröffentlicht: (2022-08-01)

Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
von: Muskan Agarwal MD, et al.
Veröffentlicht: (2023-10-01)

A case of Sjögren syndrome and anti-neutrophil cytoplasmic antibody-associated vasculitis
von: K. Kaynar, et al.
Veröffentlicht: (2023-07-01)

Testicular granulomatous vasculitis mimicking testicular torsion in an anti-neutrophil cytoplasmic antibody–associated vasculitis patient
von: Liye Suo, et al.
Veröffentlicht: (2019-01-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
von: Naidan Zhang, MS, et al.
Veröffentlicht: (2022-06-01)

Clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in French children
von: Salomon R, et al.
Veröffentlicht: (2011-09-01)

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis
von: CM Wortel, et al.
Veröffentlicht: (2025-02-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
von: David Massicotte-Azarniouch, et al.
Veröffentlicht: (2024-08-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
von: Mukhtyar, C, et al.
Veröffentlicht: (2006)

Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
von: Zhi-Ying Li, et al.
Veröffentlicht: (2020-08-01)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
von: Moog P, et al.
Veröffentlicht: (2015-11-01)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
von: Despina Michailidou, et al.
Veröffentlicht: (2022-06-01)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
von: McLaren, J, et al.
Veröffentlicht: (2001)

Anti-neutrophil cytoplasmic antibody–associated vasculitis complicated with diffuse alveolar haemorrhage and central nervous system vasculitis
von: Takashi Nawata, et al.
Veröffentlicht: (2021-04-01)